Novartis Ag Stock News

New Technologies Can Help Achieve Biden''s Ambitious Cancer Goal Authored by Amy Israel via RealClear Science (emphasis ours), President Biden has reinvigorated his cancer moonshot initiative with an ambitious goal of halving deaths in 25 years . Meeting that target will require substantial new commitments – not only from the U.S. government, but also from public and private partners around the world. With healthcare systems still reeling from the COVID-19 pandemic, smart deployment of new technologies in cancer care can help budgets go farther while closing access gaps and improving patient experiences. (AP Photo/Eric Gay) Hypofractionated radiation treatment (HRT) is a great example of how technology is transforming the fight against cancer. This method improves upon conventional treatment by concentrating larger doses of cancer-killing therapy in fewer sessions. Although HRT was first used more than a century ago, it wasn’t sustainable because of the damage caused to surrounding tissues.

Dallas, March 11, 2022 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the global inflammatory bowel disease treatment market is expected to grow from USD 18.47 billion in 2020 to USD 28.96 billion by 2030, at a CAGR of 4.6% during the forecast period 2021-2030. Inflammatory bowel disease (IBD) is a term for illnesses involving chronic inflammation of the digestive tract. Some common symptoms of IBD are: abdominal pain, weight loss, persistent diarrhea, rectal bleeding and fatigue. Ulcerative colitis and Crohn''s disease are the two most common kinds of IBD. The colon or large intestine are the only parts of the body affected by ulcerative colitis. On the other hand, Crohn''s disease can affect any portion of the gastrointestinal tract, from the mouth to the anus. The last part of the small intestine or the colon, or both, are the most usually affected areas. Anti-inflammatory drugs are frequently used as the first line of treatment against inflammatory bowel disease.

In an unusual arrangement, the Swiss pharma will make Carisma Therapeutics'' experimental cell therapy at its Morris Plains factory, part of its plans to build up a CMO business.

The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG''s (NYSE: NVS ) Kisqali (ribociclib) plus letrozole demonstrating a statistically significant improvement in overall survival. MONALEESA-2 overall survival data were first presented at the European Society for Medical Oncology Congress in September 2021. The NEJM publication includes additional analyses substantiating the longest … Full story available on Benzinga.com

Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.

Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.

Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders

Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders The post Novartis and Voyager Therapeutics reach licence option agreement for next-generation gene therapy vectors for neurological diseases appeared first on Express Pharma .

Novartis is paying Voyager Therapeutics $53 million up front to begin a partnership focused on the discovery of capsids for central nervous system disorder gene therapies. Depending on the progress of the research, Voyager could earn up to $1.5 billion in milestone payments.

Gainers Enservco Corporation (NYSE: ENSV ) surged 228% to $8.20 after jumping around 85% on Monday. Hycroft Mining Holding Corporation (NASDAQ: HYMC ) rose 168% to $0.8850. Hycroft recently reported preliminary FY21 operating results. Nine Energy Service, Inc. (NYSE: NINE ) jumped 105.9% to $7.39 after the company reported upbeat Q4 results. The company’s stock jumped over 99% on Monday. U.S. Energy Corp. (NASDAQ: USEG ) gained 77.4% to $11.21. TMC the metals company Inc. (NASDAQ: TMC ) rose 57% to $2.5912 after climbing 18% on Monday. Marine Petroleum Trust (NASDAQ: MARPS ) rose 56.8% to $18.98 after jumping around 70% on Monday. Polar Power, Inc. (NASDAQ: POLA ) gained 52% to $6.24 on continued momentum as a surge in oil prices lifts alternative energy names. Sunworks, Inc. (NYSE: SUNW ) surged 48% to $4.65. amid continued market volatility stemming from the Russia-Ukraine war. US President Biden confirmed a ban on Russian oil imports. Independence Contract Drilling, Inc. (NYSE: ICD ) gained 44% to $7.25.

The deal, which carries a $54 million upfront payment, could give Novartis access to as many as five of Voyager''s capsids, which would be used to develop gene therapies for the central nervous system.

Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more

Voyager Therapeutics Inc.''s stock gained 16.8% in premarket trading on Tuesday after the gene therapy company said it inked a deal with Novartis [n: nvs] worth up to $1.7 billion. Novartis will pay $54 million upfront to license Voyager''s novel adeno-associated virus (AAV) capsids for use with the gene therapies it''s developing. There are several additional milestones included in the deal that would bring the total value up to $1.7 billion. Voyager''s stock is down 28.5% over the past year, while the broader S&P 500 is up 14.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas

Novartis AG (NYSE: NVS ) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR ) for three capsids to use in potential gene therapies for neurological diseases, with an option to access capsids for two other targets. Data suggest that AAV capsids emerging from Voyager''s TRACER platform (Tropism Redirection of AAV by Cell type-specific Expression of RNA) … Full story available on Benzinga.com